Previous 10 | Next 10 |
Researchers from Sorbonne University have found that ketamine can reduce depression symptoms in patients with treatment-resistant depression (TRD) just four hours after infusion. Compared to healthy controls, patients with TRD reported feeling more optimistic a few hours after ketamine infusion...
2023-10-26 08:37:34 ET More on COMPASS Pathways ADS Compass Pathways: Debt Deal Secured, Cash Runway Extended Psychedelics research amendments advance in House committee For further details see: COMPASS Pathways CFO Falvey to step down
LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update o...
2023-10-19 10:10:00 ET October 19, 2023 (Investorideas.com Newswire) Investorideas.com ( https://www.investorideas.com ) a global investor news source covering psilocybin and psychedelic health and wellness stocks releases a special news report featuring Kaya Holdings, Inc. ( OTCQB:KA...
2023-10-18 07:48:55 ET Companies mentioned in this editorial; Lucy Scientific Discovery Inc. (NASDAQ: LSDI), Compass Pathways (NASDAQ: CMPS), Mind Medicine Inc (NASDAQ: MNMD), Overstock.com Inc. (NADAQ: OSTK), and Constellation Brands (NYSE: STZ) and Canopy Growth (NYSE: CGC). DENVER, C...
Scientists are working on technology that could alleviate the anxiety related to psychedelic sessions and aid in treating post-traumatic stress disorder ( PTSD ). Apollo Neuroscience has developed a wearable device called the Apollo wearable that can be worn on the ankle or wrist and produce si...
(NewsDirect) By Faith Ashmore, Benzinga Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among patients with conditions like treatment-resistant dep...
2023-10-11 17:30:06 ET Gainers: COMPASS Pathways ( NASDAQ: CMPS ) +5% . Inozyme Pharma ( INZY ) +4% . CommScope Holding ( COMM ) +4% . FTAI Infrastructure ( FIP ) +3% . Aemetis ( AMTX ) +3% . Losers: Lottery ( ...
A recent study from The Ohio State University’s Center for Psychedelic Drug Research sought to determine if psychiatrists, psychologists and social workers are on the same page regarding the swiftly growing psychedelic therapy field. The research team was specifically interested in asses...
(NewsDirect) By Faith Ashmore, Benzinga The Current Landscape Of Mental Health Is Failing Patients Mental health treatments often fail many patients, leaving them struggling to find relief and support. Patients in this category are often considered “treatment-resistant,”...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...